-
Congratulations! LYHER Self-Testing Series New Arrival
On May 6th , 2022, LYHER Self-Testing Series new products have obtained CE certificates, such as COVID-19 and Influenza A/B Antigen Test Kit for self-testing , SARS-CoV-2 Antigen Rapid Test for self-testing(Saliva), which are independently researched andRead more -
Hangzhou Laihe Biotech Co., Ltd helps to fight the epidemic
Hangzhou Laihe Biotech Co., LtdWe, Hangzhou Laihe Biotech Co., LTD. has always focused on the development and industrialization of POCT instant diagnosis, monitoring and health information technology field. Our company integrates R&D, production, sales anRead more -
European CE0197 for self-testing approved! LYHER Novel Coronavirus COVID-19 Antigen Test Kit for self-testing is widely popular in Europe!
European CE0197 for self-testing approved! LYHER Novel Coronavirus COVID-19 Antigen Test Kit for self-testing is widely popular in Europe!Since the outbreak of COVID-19, the global epidemic prevention and control has never been slackened.Recently, the NoRead more -
“World Drug Report 2021″: About 275 million people worldwide use drugs! Drugs of Abuse hair detaction is necessary.
Recently, the United Nations Office on Drugs and Crime (UNODC) released the "World Drug Report 2021." The report shows that about 275 million people worldwide used drugs last year. About 5.5% of the population aged 15-64 had used drugs at least once in thRead more -
The secretary of the district party committee has visited our company for guidance and exchange.
On the afternoon of March 10th, Wang Min, Secretary of the High-tech District Committee, visited Hangzhou Laihe Biotech Co., Ltd., accompanied by Shang Liping, member of the Standing Committee and Organization Minister of the District Committee, and leadeRead more -
Liver cancer is one of the most common malignant tumors in the world
Liver cancer is one of the most common malignant tumors in the world, and the number of liver cancer patients in my country accounts for more than half of the world.It is estimated that 70 to 80 percent of patients with liver cancer are already in the midRead more
Privacy settings